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patients with PDHC deficiency and other diseases that cause lactic acidosis.
phenylbutyrate is already used in human patients and known to be safe, we may soon see a new treatment option for 
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protected the complex from inactivation and increased its enzyme activity in both wild-type fibroblasts and those 
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4Lactic acidosis is a buildup of lactic acid in the blood and tissues, which can be due to several inborn errors of
metabolism as well as nongenetic conditions. Deficiency of pyruvate dehydrogenase complex (PDHC) is the most
common genetic disorder leading to lactic acidosis. Phosphorylation of specific serine residues of the E1a subunit of
PDHC by pyruvate dehydrogenase kinase (PDK) inactivates the enzyme, whereas dephosphorylation restores PDHC
activity. We found that phenylbutyrate enhances PDHC enzymatic activity in vitro and in vivo by increasing the
proportion of unphosphorylated enzyme through inhibition of PDK. Phenylbutyrate given to C57BL/6 wild-type
mice results in a significant increase in PDHC enzyme activity and a reduction of phosphorylated E1a in brain,
muscle, and liver compared to saline-treated mice. By means of recombinant enzymes, we showed that phenylbu-
tyrate prevents phosphorylation of E1a through binding and inhibition of PDK, providing a molecular explanation
for the effect of phenylbutyrate on PDHC activity. Phenylbutyrate increases PDHC activity in fibroblasts from PDHC-
deficient patients harboring various molecular defects and corrects the morphological, locomotor, and biochemical
abnormalities in the noam631 zebrafish model of PDHC deficiency. In mice, phenylbutyrate prevents systemic lactic
acidosis induced by partial hepatectomy. Because phenylbutyrate is already approved for human use in other dis-
eases, the findings of this study have the potential to be rapidly translated for treatment of patients with PDHC
deficiency and other forms of primary and secondary lactic acidosis. 
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 INTRODUCTION
Lactic acid is the product of anaerobic metabolism of glucose and is
generated by reduction of pyruvate. Patients with inborn errors of
metabolism, including mitochondrial oxidative phosphorylation de-
fects and disorders of gluconeogenesis, as well as several nongenetic
diseases, present with lactic acidosis. Pyruvate dehydrogenase complex
(PDHC), an enzyme complex that catalyzes the irreversible conver-
sion of pyruvate into acetyl-CoA (coenzyme A), plays a central role
in linking glycolysis to the tricarboxylic acid (TCA) cycle and lipo-
genic pathways (1). The oxidative metabolism of pyruvate, the end
product of glycolysis, proceeds through PDHC into the TCA cycle and
the mitochondrial respiratory chain. A deficiency of any enzyme in
these pathways results in inadequate removal of pyruvate and lactate
from blood and tissues and causes lactic acidosis. Deficiency of the
nuclear-encoded PDHC is one of the most common inborn errors of
mitochondrial energy metabolism. Most patients show progressive neu-
rological degeneration and either persistent or episodic elevation of lac-
tate in blood, cerebrospinal fluid (CSF), or both. These patients present
with a graded spectrum of severity ranging from the most severe Leigh
syndrome with overwhelming lactic acidemia and death in the neo-
natal period to a milder form with carbohydrate-induced ataxia (2, 3).
The severity of the disease is a function of the severity of lactic acidosis
and degree of residual enzymatic activity (2, 4). Currently, there are no
proven treatments for PDHC deficiency. Anecdotal studies have re-1Telethon Institute of Genetics and Medicine, Naples 80131, Italy. 2Institute of Protein
Biochemistry, Naples 80131, Italy. 3Besta Institute, Milan 20126, Italy. 4Stazione Zoologica
Anton Dohrn, Naples 80121, Italy. 5Departments of Medicine and Biochemistry and
Molecular Biology, University of Florida College of Medicine, Gainesville, FL 32610, USA.
6Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX
77030, USA. 7Howard Hughes Institute, Baylor College of Medicine, Houston, TX 77030,
USA. 8Department of Pediatrics, Federico II University of Naples, Naples 80131, Italy.
*To whom correspondence should be addressed. E-mail: brunetti@tigem.it
www.Scieported beneficial effects from the use of high-fat, ketogenic diets,
which provide an alternative energy source to carbohydrate (5–7).
Availability of PDHC substrates [pyruvate and adenosine diphosphate
(ADP)] results in inhibition of pyruvate dehydrogenase kinase (PDK)
(8) and PDHC activation. On the basis of this inhibitory role, pyruvate
administration has been attempted in patients with PDHC deficiency
(9–11). Dichloroacetate (DCA), a pyruvate analog, also increases PDHC
activity and is effective in reducing blood, CSF, and brain lactate,
thus improving morbidity in patients with deficiency of PDHC, res-
piratory chain defects, or mitochondrial DNA (mtDNA) mutations
(12). However, in a controlled trial in children with various forms of
congenital lactic acidosis, chronic DCA administration did not result
in improvements of neurologic problems and other clinical outcomes
(13). Moreover, DCA has raised some concerns because it has been
associated with hepatocellular and peripheral nerve toxicity, particu-
larly in adults (14). Therefore, investigations of effective treatments for
PDHC deficiency are highly needed.
PDHC consists of three different enzymes: (i) thiamine diphosphate
(ThDP)–dependent pyruvate dehydrogenase (E1), a heterotetrameric
(a2b2) protein that irreversibly oxidizes pyruvate to acetyl-CoA; (ii) di-
hydrolipoamide acetyltransferase (E2), which forms the structural core
of the complex; and (iii) flavin adenine dinucleotide–containing dihy-
drolipoamide dehydrogenase (E3), which is integrated into the complex
by an E3-binding protein (E3BP). In humans, the disease due to PDHC
deficiency may be caused by defects in E1, E2, or E3 components of the
complex or to a deficiency of E3BP or PDHC phosphatase (2, 3).
PDHC is one of the highly conserved mitochondrial a-ketoacid de-
hydrogenase complexes, which include the branched-chain a-ketoacid
dehydrogenase (BCKDC), the a-ketoglutarate dehydrogenase complex,
and PDHC (1). Phosphorylation of PDHC by PDK was discovered in
the late 1960s and is among the first examples of enzyme regulation
dependent on reversible phosphorylation (15). Phosphorylation ofnceTranslationalMedicine.org 6 March 2013 Vol 5 Issue 175 175ra31 1
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4E1a occurs at three serine residues (Ser264-a, site 1; Ser271-a, site 2; and
Ser203-a, site 3). Phosphorylation at any of these sites inactivates PDHC
(16). Four isoforms of PDK (PDK1, PDK2, PDK3, and PDK4) are
known to phosphorylate the E1a subunit of PDHC, thereby reducing
the activity of the complex (17–19). Conversely, dephosphorylation of
these residues by pyruvate dehydrogenase phosphatases (PDP1 and
PDP2) restores PDHC activity (19).
We have recently discovered that phenylbutyrate is an effective
treatment for patients with maple syrup urine disease (MSUD), which
is caused by mutations in one of the components of BCKDC (20). We
found that phenylbutyrate significantly reduces the plasma concentra-
tions of branched-chain amino acids and their corresponding branched-
chain ketoacids in patients with MSUD and inhibits the kinase of
BCKDC (BDK) (20). Similarly to PDHC, BCKDC is tightly regulated
by reversible phosphorylation of the E1 subunit. Moreover, mitochondri-
al protein kinases, including PDKs and BDK, are members of the same
family of protein kinases (21). On the basis of these observations, we
hypothesized that phenylbutyrate would enhance PDHC enzyme activity
by increasing the proportion of unphosphorylated enzyme and improve
the phenotype of PDHC deficiency. 
o
n
 A
pr
il 1
st
m
.s
ci
en
ce
m
ag
.o
rg
ro
m
 RESULTS
Phenylbutyrate increases unphosphorylated PDH-E1a and
PDHC enzyme activity in human fibroblasts
To investigate the efficacy of phenylbutyrate in altering PDHC phos-
phorylation and activity, we treated wild-type human fibroblasts with
different concentrations of phenylbutyrate (0.25, 0.5, and 1 mM) for
up to 24 hours. By Western blot analysis with an antibody specific for
phosphorylated E1a subunit of PDHC, we observed a significant (P <
0.05) reduction in the amount of phosphorylated E1a compared to
the untreated cells, with all three concentrations of phenylbutyrate tested
for 24 hours (Fig. 1, A and B). No changes were observed in the amountD
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fof phosphorylated E1a after 2 and 6 hours
of incubation with phenylbutyrate (fig.
S1). The results were confirmed on a sec-
ond independent fibroblast cell line (fig.
S2). We next determined PDHC enzyme
activity in fibroblasts incubated with phe-
nylbutyrate. PDHC activity was found to
be increased 1.4- and 2.2-fold over base-
line untreated levels in two independent
cell lines (P < 0.05) (Fig. 1C). Because of
reports that phenylbutyrate can function
as a histone deacetylase inhibitor (22), we
studied phenylbutyrate-treated fibroblasts
and measured the RNA levels of PDHC
subunits, testis-specific PDHA2 (23), PDPs,
and PDKs to determine whether increased
transcription of PDHC or its regulatory en-
zymes contributes to elevated enzyme activ-
ity. We found that concentrations of mRNA
transcribed from the genes PDHA1, PDHA2,
pyruvate dehydrogenase E1b (PDHB), di-
hydrolipoamide S-acetyltransferase (DLAT),
dihydrolipoamide dehydrogenase (DLD),
PDP1, PDP2, component X of the PDHCwww.Scie(PDHX), PDK1, PDK2, PDK3, and PDK4 were unchanged in fibro-
blasts treated with 1 mM phenylbutyrate compared to untreated cells
(fig. S3). These results indicate that the effect of phenylbutyrate on en-
zyme activity and inhibition of E1a phosphorylation is not mediated by
increased RNA expression of genes encoding subunits of the complex
or its regulatory enzymes.
Phenylbutyrate increases unphosphorylated PDH-E1a and
PDHC enzyme activity in mouse brain, muscle, and liver
To investigate the effect of phenylbutyrate in vivo, C57BL/6 wild-type
mice (at least n = 5 per group) were given either saline or phenylbu-
tyrate (250 or 500 mg/kg per day, divided into three administrations)
orally by gavage, and after 3 days of treatment, they were sacrificed for
analyses. Both phenylbutyrate and phenylacetate (a metabolite of
phenylbutyrate) were undetectable by tandem mass spectrometry on
serum samples collected at the time of sacrifice (1.5 hours after the
last drug administration) in mice treated with 250 mg/kg per day.
Phenylacetate and trace amounts of phenylbutyrate were, however,
detected in the sera of mice treated with phenylbutyrate (500 mg/kg
per day) (table S1). Western blot analysis of brain and muscle mito-
chondrial extracts showed that both doses of phenylbutyrate resulted
in a significant (P < 0.05) reduction of phosphorylated E1a subunit of
PDHC (PDH-E1a-Ser203, PDH-E1a-Ser264, and PDH-E1a-Ser271) com-
pared to saline-treated mice (Fig. 2 and fig. S4). Reduction of phos-
phorylated E1a subunit of PDHC (PDH-E1a-Ser203 and PDH-E1a-Ser271)
was also detected in the livers of treated animals compared to saline-
treated mice at the dose of 250 mg/kg per day, but PDH-E1a-Ser264
amount was reduced in the liver only at the higher dose of 500 mg/kg
per day (Fig. 2 and fig. S4). Phenylbutyrate did not have an effect on
total E1a subunit protein (PDH-E1a; Fig. 2 and fig. S4). The less
prominent effect on phosphorylated E1a in the liver compared to
brain and muscle is likely dependent on the hepatic inactivation
of phenylbutyrate. In humans, phenylbutyrate is rapidly converted
to phenylacetate by hepatic b-oxidation and is undetectable inFig. 1. PDHC phosphorylation and activity after drug
treatment of human wild-type (WT) fibroblasts. (A) West-
ern blotting of BA1054 fibroblasts treated with 0.25, 0.5,
or 1 mM phenylbutyrate for 24 hours, or untreated. The
images are representative of two independent experi-
ments. (B) The average band intensities of phosphoryl-
ated E1were normalized for total E1 from two independent
experiments. (C) Two independent fibroblast cell lines
(BA1054 and BA1020) were treated with phenylbutyrate
at 1 mM for 24 hours before measurement of PDH en-
zyme activity. *P < 0.05; **P < 0.01.nceTranslationalMedicine.org 6 March 2013 Vol 5 Issue 175 175ra31 2
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 the serum by 6 hours after oral admin-
istration (24, 25). Together, these results
show that phenylbutyrate increases the
proportion of active and unphosphoryl-
ated enzyme but does not affect total E1
levels in vivo. The increase in the active
form of PDHC was detected in brain and
muscle, the tissues most affected by PDHC
deficiency disease.
Compared to saline controls (n = 16),
PDHC enzyme activity in brain mitochon-
drial extracts of mice treated with phenyl-
butyrate [250 mg/kg per day (n = 10) and
500 mg/kg per day (n = 8)] was found to
be increased 1.5-fold (P < 0.01) and 2.8-
fold (P < 0.01), respectively (Fig. 3).
We also evaluated the amounts of Pdhc
subunits, Pdp, and Pdk in brain RNA to
determine whether increased transcription
of PDHC, PDHA2, or its regulatory en-
zymes could contribute to elevated enzyme
activity. The amounts of mRNA of Pdha1,
Pdha2, Pdhb, Dld, Dlat, Pdk1, Pdk2, Pdk3,
Pdk4, Pdp1, and Pdp2 were unchanged in
brains of mice treated with phenylbutyrate
(250 or 500 mg/kg per day) compared to
untreated animals (fig. S5). Similarly, the
same mRNAs were unchanged in muscles
of mice treated with 500 mg/kg per day
compared to saline-treated controls (fig.
S6). These results suggest that the primary
effect of phenylbutyrate is on enzyme ac-
tivity and PDK-mediated phosphorylation
of E1a and is not mediated by increased
RNA expression of the genes encoding
PDHC or its regulatory enzymes in bothD
ow
nl
oabrain and muscle.
Phenylbutyrate inhibits E1a phosphorylation by
PDK inhibition
Because of the previously shown effect of phenylbutyrate on BDK
(20), we assayed for the ability of PDK to inactivate E1 in the presence
and absence of phenylbutyrate. At saturating concentrations of E1a
(4.2 mM), only slight PDK inhibition was observed (7%; 195 or 210
nmol/min per mg of enzyme with or without the inhibitor, respec-
tively), but at nonsaturating concentrations of E1a, phenylbutyrate
prevented inactivation of E1 in the presence of PDK (Fig. 4A) by
acting as a competitive inhibitor with a Ki (inhibition constant) of
0.33 ± 0.08 mM (Fig. 4B). These results suggest that phenylbutyrate
protects PDHC from inactivation by competing for binding of E1a
to PDK. To confirm that phenylbutyrate binds to PDK, we carried
out a docking simulation, which revealed two putative binding sites
of phenylbutyrate to PDK2: one site was found near the adenosine
triphosphate (ATP) lid (Fig. 4, C and D) with a binding energy of
−4.0 kcal/mol and theoretical Ki of 1.2 mM and another site corre-
sponded to the site of binding of PFz3, a PDHK inhibitor (Fig. 4, E
and F), with a binding energy of −5.06 kcal/mol and a theoretical Ki
of 0.197 mM.www.SciePhenylbutyrate increases PDHC enzyme activity in
PDHC-deficient fibroblasts
To evaluate phenylbutyrate’s potential for enhancing PDHC enzyme
activity in PDHC deficiency, we investigated its effects in fibroblastsFig. 3. Analysis of PDHC activity in mouse brain. PDHC activity was mea-
sured in brain mitochondrial extracts of mice treated with phenylbutyrate
[250 mg/kg per day (n = 10) or 500 mg/kg per day (n = 8)] and in saline
controls (n = 16). **P < 0.01.Fig. 2. PDHC phosphorylation status in mouse tissues. Western blot analysis of brain, muscle, and
liver mitochondrial extracts was performed with antibodies against the phosphorylated form of E1a
(P-E1a). Each lane corresponds to brain, muscle, or liver mitochondrial extracts from an independent,
representative mouse. Total E1a protein and cytochrome c oxidase (COX) are shown as controls. The
graphs present densitometric quantification of n = 5 mice from each treatment group. Means ±
SDs are shown. *P < 0.05; **P < 0.01.nceTranslationalMedicine.org 6 March 2013 Vol 5 Issue 175 175ra31 3
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from patients with PDHC deficiency due to mutations in PDHA1 or
PDHX genes (Table 1). Most mutations resulted in detection of mutated
proteins by Western blot analysis in fibroblasts (fig. S7). PDHC-deficient
cells were incubated with phenylbutyrate under optimal conditions (1 mM
for 24 hours), and mitochondrial extracts were prepared to measure
enzyme activity. Phenylbutyrate increased PDHC enzyme activity in 8
of 12 cell lines with PDHA1 defects and in 1 of 2 cell lines with PDHX
mutations (Fig. 5 and Table 1). To correlate genotype with drug re-
sponse, we mapped phenylbutyrate-responsive and nonresponsive amino
acid substitutions on the three-dimensional (3D) structure of the E1a
protein (Fig. 6). Mutations resulting in phenylbutyrate-mediated increase
of PDHC activity (p.V138M; p.P221T, p.N135S; p.Y214C; p.R234G)
were localized closer to the catalytic site of the enzyme than were mu-www.ScienceTranslationalMedicine.orgtations that were not associated with a
drug-induced increase of PDHC activity
(p.R349H; p.M181V). Because the sites of
phosphorylation that regulate PDHC ac-
tivity are located near the active site of the
enzyme, our findings are consistent with the
notion that phenylbutyrate acts to mitigate
PDK-dependent E1a phosphorylation.
Phenylbutyrate corrects the
morphological and biochemical
phenotype of noam631 zebrafish
Targeted disruption of the E1a and E3
subunits in mice results in embryonic le-
thality (26, 27); thus, these animals have
limited utility for investigation of novel
therapies. In contrast, the no optokinetic
response a (noa) mutant zebrafish is avail-
able as a model of PDHC deficiency (28, 29).
The noam631 zebrafish shows expanded
melanophores (28), absence of feeding be-
havior, lethargy, and premature death (30).
These mutant fish also show elevations of
lactate and pyruvate. The noam631 zebrafish
mutant harbors a missense mutation at co-
don 644 in the DLAT gene, encoding the
E2 subunit of PDHC (31).
Wild-type zebrafish have the ability to
adjust melanin pigment levels in response
to light or dark background. A marked
phenotype of noa mutants is a dark pig-
mentation due to expanded melanophores
(28), a trait common to zebrafish vision
mutants (32), presumably due to poor de-
tection of light. When noam631 mutants
were treated with phenylbutyrate, a de-
crease in melanophore expansion was ob-
served (Fig. 7A). Untreated mutants lay
lethargically and floated on their side or
back. In contrast, phenylbutyrate-treated
noam631 larvae showed active locomotion
behavior (Fig. 7B).
Elevated levels of lactate and pyruvate
are biochemical hallmarks of PDHC de-
ficiency (3). We determined the concentra-tions of these metabolites in homogenates of phenylbutyrate-treated
mutants and controls. In the phenylbutyrate-treated fish, we observed a
2-fold reduction in lactate (Fig. 7C) and a 1.6-fold reduction in pyru-
vate compared to untreated mutants (Fig. 7D). These data suggest that
phenylbutyrate reduces the detrimental lactic acidosis in the zebrafish
PDH-deficient model.
Phenylbutyrate prevents lactic acidosis induced by
partial hepatectomy
The liver is the principal organ responsible for the clearance of blood
lactate (33–35). Partial hepatectomy has been experimentally used in
animal models to induce systemic lactic acidosis (36). We performed
partial hepatectomy in mice that were treated with phenylbutyrateFig. 4. PDK inhibition by phenylbutyrate. (A) Lineweaver-Burk plot of WT recombinant E1a in the
absence ( ) or presence of 0.25 mM ( ), 0.5 mM (□), and 1 mM (○) phenylbutyrate. (B) Replot of slopes▪ •
measured from (A) against the concentration of phenylbutyrate. The intersection of the line with the x
axis gives the value of Ki. (C and E) Phenylbutyrate (PB; stick representation) in the two identified
pockets on the protein surface of PDK2. (D and F) Specific interactions of phenylbutyrate with amino
acid residues (stick representation) at the binding sites. Van der Waals interaction spheres of the amino
acid residues (stick representation) in contact with the inhibitor have been removed for clarity.6 March 2013 Vol 5 Issue 175 175ra31 4
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 (500 mg/kg per day, divided into three daily doses) from the day
before the partial hepatectomy up to 72 hours after the intervention
and found that phenylbutyrate prevented blood accumulation of lac-
tate in hepatectomized mice (Fig. 8).DISCUSSION
There is currently no proven treatment for patients with PDHC defi-
ciency. Through a combination of studies in cells, mice, and the zebra-www.ScienceTranslationalMedicine.orgfish disease model, we demonstrate that
phenylbutyrate may be a potential treat-
ment for patients with PDHC deficiency.
The results of this study show that phenyl-
butyrate enhances the activity of PDHC
throughout the body, including the brain,
which is one of the most affected tissues in
PDHC deficiency. Given that phenylbutyr-
ate is a drug already approved for use in
humans, and its safety profile is well known
(37), these findings have the potential to be
rapidly translated to clinical trials for pa-
tients with PDHC deficiency.
By means of recombinant enzymes, we
showed that phenylbutyrate directly inhib-
its the PDK2, thus providing a molecular
explanation for the effect of phenylbutyr-
ate on PDHC activity. We also predicted
that the binding of phenylbutyrate to PDK2
would occur near the ATP lid in proximityof Tyr208-a, thereby reducing PDK2 activity (38). This binding site
found only on PDK2 have not been previously recognized as inhibitor
binding sites of PDK. When a nucleotide binds to the ATP-binding
pocket, the ordered ATP lid must be reorganized to accommodate the
phosphate group of the nucleotide. The inherent flexibility of the ATP
lid similarly allows binding of the inhibitor that interferes with the
ATP-ADP cycle. In BDK, the ATP lid is largely disordered, even when
nucleotide is bound (39), thus supporting the hypothesis that full
ordering requires both nucleotide binding and specific protein-protein
interactions. For BDK and PDKs, such interactions are likely providedTable 1. PDHC-deficient fibroblasts.Patient no. Gender
Enzyme activity
(% of normal control)Molecular defect*Affected gene Allele 16 March 2013 Vol 5 IssueAllele 21 Female 33 PDHA1 p.V138M Wild type2 Male 24 PDHA1 p.N135S —3 Male 44 PDHA1 p.R349H —4 Female 65 PDHA1 p.R275* Wild type5 Female 46 PDHA1 c.904-928inv25 Wild type6 Male 15 PDHA1 p.M181V —7 Female 38 PDHA1 p.Y214C Wild type8 Female 44 PDHA1 c.1063-1068del5 Wild type9 Male 25 PDHA1 c.1159AAGTdup —10 Male 25 PDHA1 c.1159AAGTdup —11 Male 45 PDHA1 p.R234G —12 Male 70 PDHA1 p.P221T —13† Female 46 N.D. N.D. N.D.14 Male 11 PDHX p.Q219* c.1122_1125del15 Male 12 PDHX 10 kb del (ex 5–6) 10 kb del (ex 5–6)*Nucleotides are reported according to the National Center for Biotechnology Information (NCBI) gene sequence (NM_000284.3 for PDHA1 and NM_003477.2 for PDHX). The amino acid positions
of the mutations are reported considering the mature NCBI protein sequence (NP_000275.1 for PDHA1 and NP_003468.2 for PDHX) after signal peptide cleavage. †This patient was found to
have PDH deficiency due to abnormal ubiquitination and proteasome degradation of E1b encoded by PDHB1 gene, as previously described (66). N.D., not detected.Fig. 5. PDHC activity in PDHC-deficient cells. PDHC activity is shown for WT control (white bar) and
PDHC-deficient cells incubated with phenylbutyrate. The molecular defects of the corresponding pa-
tient cell lines are shown in Table 1. Patients 1 to 12 (dark gray bars) have mutations in PDHA1, patient
13 (light gray bar) has PDHC deficiency due to abnormal ubiquitination and degradation of E1b (66),
and patients 14 and 15 (black bars) have mutations in PDHX. *P < 0.05.175 175ra31 5
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 by their corresponding E1 substrates and/or lipoyl-bearing domains of
the E2 core (40–42). The conformational changes induced by phenyl-
butyrate binding to PDK could interfere with E1a binding, thus
supporting the competitive inhibition.
PDHC enzyme activity was increased by phenylbutyrate in fibro-
blasts from some of the patients with impaired PDHC activity caused
by various molecular defects. Phenylbutyrate-responsive mutations are
all located near the active site of E1. Crystal structure of the hetero-
tetrameric (a2b2) E1 protein shows that active sites 1 and 2 are located
in the conserved phosphorylation loop A (Ph-loop A, residues from
259-a to 282-a), which forms the wall of the E1a active-site channel
and anchors the ThDP to the active site (43). Site 3 is located in the
short phosphorylation loop B segment (Ph-loop B; residues from 198-a
to 205-a) and provides coordination with a Mg2+ ion chelated by the
diphosphate group of ThDP. Phosphorylation of Ser264-a (site 1) pre-
vents the cofactor ThDP-induced ordering of the Ph-loops A and B
that carry the three phosphorylation sites. The disordering of these
loops is caused by a steric hindrance between the phosphorylation group
at site 1 and the nearby Ser266-a, which abolishes a hydrogen-binding
network essential for maintaining the loop conformations. The unstruc-
tured loops impair binding of lipoyl domains of the PDHC core to E1a,
negating the reductive acetylation step that disrupts substrate channeling
by PDHC and leads to inactivation of the catalytic machinery (44). It
is likely that phenylbutyrate-responsive PDHC-deficient cells harbor
mutations that are located at the active site and quench PDHC activity
by mimicking or potentiating the disordering effect of phosphorylation.
Inhibition of phosphorylation by phenylbutyrate relieves the inhibitory
effect of such mutations. For example, Val138-a from the E1a chain is lo-
cated in the loop 136 to 140. The p.V138M mutation (patient 1) may
result in steric hindrance with ThDP that hampers ThDP reorganizationwww.ScienceTranslationalMedicine.orgof loops around the active site, thus affect-
ing PDHC activity. A similar effect can be
envisaged for the p.N135Smutation (patient
2) that may push ThDP against Val138-a.
Pro221-a is responsible for the turn determin-
ing the orientation of region 198 to 205,
bearing the Ser203-a phosphorylation site.
Therefore, the p.P221T mutation (patient
12) may affect the structural organization
of the active site. Tyr214-a is inside the loop
containing Ser203-a and binds by hydropho-
bic interactions the N-terminal region of
E1a (residues 13 and 15) as well as the res-
idues Gly222-a-Arg224-a close to Pro221-a. There-
fore, the replacement of Tyr214-a with a Cys
residue (patient 7) can account for the re-
duced enzyme activity. The p.R234G muta-
tion (patient 11) is located inside the a-helix
230–245 and contributes to anchoring the
helix to other portions of the N terminus
(Val25-a, Thr26-a, Tyr35-a); in this case, it is dif-
ficult to rationalize the positive effect of
phenylbutyrate on PDHC activity because
this residue is more distant from the active
site. The residuesMet181-a andArg349-a, which
are mutated in phenylbutyrate nonrespon-
sive cells from patients 6 and 3, respective-
ly, are distant from the active site and fromthe phosphorylation sites. It is conceivable that the inactivating effect of
the mutations affecting these residues is due to a mechanism different
from phosphorylation/dephosphorylation, and not susceptible to phenyl-
butyrate. Arg349-a forms a salt bridge with Glu281-b and a hydrogen bond
with Pro267-a. These interactions can be changed by replacing arginine
with histidine (patient 3), therefore producing structural changes in the
oligomeric structure of the enzyme. Likewise, Met181-a forms hydrophobic
interactions with a cluster of hydrophobic residues from chain b. Muta-
tion to valine (patient 6) could drastically weaken this interaction that
anchors a-helix 59–72 from chain b to chain a. Mutation p.E275*, which
deletes the C terminus of E1a, has either the same effect as mutation 349
or more disruptive effects.
Most (84%) of the patients with PDHC deficiency have mutations
in the PDHA1 gene (3) and thus are potential candidates for phenyl-
butyrate therapy. It remains to be investigated whether patients carry-
ing molecular defects in genes encoding the other components of the
complex are also candidates for this treatment. Given the mode of
action of phenylbutyrate, we have elucidated that PDHC deficiency
due to PDP1 defects is also highly likely to be responsive.
Lactic acidosis is a major manifestation of mitochondrial diseases
caused by pathogenic mutant mtDNA. Secondary lactic acidosis has
detrimental effects on mitochondrial disease phenotype, and inhibi-
tion of chronic lactic acidosis appears to provide clinical benefit. In
a mouse model of mitochondrial disease resulting in a defect of mito-
chondrial respiration and lactic acidosis, inhibition of lactate produc-
tion by DCA improved mitochondrial biogenesis and survival (45).
Therefore, applications of phenylbutyrate could be extended to a
broader range of mitochondrial cytopathies. Moreover, excessive lactic
acid production occurs in many nongenetic conditions associated with
blood vessel occlusion, asphyxia, liver disease, and other pathologicalFig. 6. Position of responsive and nonresponsive PDHA1 mutations. (A) Picture of heterotetrameric hu-
man E1 [Protein Data Bank (PDB): 3EXE] with the four chains highlighted (a, green; b, cyan; a′, magenta; b′,
yellow) and the positions (arrows) of nonresponsive mutations Met181-a and Arg349-a shown as ball and
stick colored in blue. The positions of Met181-a and Arg349-a are part of the a subunit and are underneath the
b subunit. The square indicates the region with phenylbutyrate-responsive mutations and is enlarged in (B).
(B) Orientation is the same as in (A). The following elements are shown: Asn135-a, Val138-a, Pro221-a, Tyr214-a,
and Arg234-a (red); phosphorylation sites Ser203-a, Ser264-a, and Ser271-a (yellow); and coenzyme ThDP (blue).
The ribbon of the N terminus (N-ter) of the E1a protein (residues 1 to 35) is depicted in gray; the structural
elements containing Pro221-a, Tyr214-a, and Ser203-a are shown in cyan. The loop containing Ser264-a and
Ser271-a is shown in magenta. The loop containing the residues Asn135-a and Val138-a is shown in green.6 March 2013 Vol 5 Issue 175 175ra31 6
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 conditions. For example, lactate, as a product of glycolysis of blood-
derived glucose, accumulates in brain during ischemic stroke (46, 47)
and results in tissue acidosis (46–49), which is detrimental for cell survival
(50, 51). Furthermore, elevation of blood glucose concentration raises lac-
tate and acidosis in ischemic brain areas and increases infarct size inwww.ScienceTranslationalMedicine.organimals (52, 53) and humans (54). The re-
duction of blood lactate in hepatectomized
mice (Fig. 8) suggests that phenylbutyrate
may be effective for the treatment of lactic
acidosis in a broad range of diseases, such
as heart ischemia, septic shock, and stroke
(55, 56). There have been already reports of
a protective effect of phenylbutyrate against
cerebral ischemic insults (57, 58), which
could be explained, at least in part, by the
effect of phenylbutyrate on PDHC phos-
phorylation reported in the present study.
In conclusion, we show that phenylbu-
tyrate inhibits PDK-mediated phosphoryl-
ation, increases PDHC activity, improves
the phenotype of the zebrafish model of
PDHC deficiency, and reduces systemic
lactic acidosis. These results may pave the
way toward a clinical trial of phenylbutyr-
ate for PDHC deficiency and possibly other
mitochondrial diseases, as well as several
nongenetic diseases with lactic acidosis.MATERIALS AND METHODS
Cell studies
The effect of phenylbutyrate on PDHC ac-
tivity was investigated in synchronized wild-
type human fibroblasts (BA1054 and
BA1020) cultured in Dulbecco’s modified
Eagle’s medium and 1% fetal bovine serum
in the presence or absence of 0.25, 0.5, or1 mM phenylbutyrate (Ammonaps, Swedish Orphan International Lab)
for 2, 6, 24, or 48 hours. PDHC-deficient cells were treated with 1 mM
phenylbutyrate for 24 hours. After drug treatment, cells were lysed in cold
lysis buffer [50 mM tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100,
1 mM EDTA, and 0.1% SDS] in the presence of protease inhibitor cocktail
(Sigma). Total proteins quantified by the Bradford method were resolved
by SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
onto a polyvinylidene difluoride (PVDF) membrane. Primary rabbit poly-
clonal PhosphoDetect anti–PDH-E1a (p-Ser264-a) (Calbiochem AP1062)
and primarymonoclonal anti–PDH-E1a (MitoSciencesMSP02) were diluted
1:500 and 1:250, respectively. Horseradish peroxidase (HRP)–conjugated sec-
ondary antibodies [ECL rabbit IgG, HRP-linked whole antibody from donkey
(GEHealthcareNA934) andECL anti-mouse IgG, HRP-linked species-specific
whole antibody from sheep (GE Healthcare NA931)] were diluted in 5%
milk in tris-buffered saline–Tween 20 (TBST). PDHC-deficient fibroblasts
were analyzed for expression of proteins of the complex with primary
monoclonal MitoProfile PDH Western blot antibodies (anti–PDH-E1a, anti–
PDH-E1b, anti–PDH-E2, and anti-E3BP) (MitoSciencesMSP02-150). Pro-
tein bands were visualized with a chemiluminescence detection system
(Pierce). Band intensities were quantified with Quantity One 1-D Analysis
Software version 4.6.7 (Bio-Rad Laboratories).
Mouse studies
Mouse studies were approved by the Italian Ministry of Health. Sodium
phenylbutyrate or saline was given orally to C57BL/6 mice (Charles RiverFig. 7. Effect of phenylbutyrate on zebrafish noam631 mutants. (A) Pigmentation phenotype of untreated
noam631, treated mutant noam631, and untreated WT larvae at 8 days after fertilization (n = 14 per group). The
bar graph shows quantification of zebrafish pigmentation, calculated with ImageJ software reporting mean
gray value for a given area. The binary representation assumes that 0 is black and the maximum value (255
at 8 bit) is white. AU, arbitrary unit. (B) Movements of the larvae are plotted as the distance traveled by the
larvae relative to time in 48-well plate, as previously described (31). (C and D) Lactate (C) and pyruvate (D)
concentrations in untreated or treated mutant noam631 larvae and in WT larvae (n = 6 per group). *P < 0.05.Fig. 8. Effect of phenylbutyrate on blood lactate on hepatectomized mice.
Blood lactate concentration at specified time intervals after partial hepatec-
tomy in mice treated with saline or phenylbutyrate (n = 5 per group). *P <
0.05; **P < 0.01.6 March 2013 Vol 5 Issue 175 175ra31 7
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 Laboratories) by gavage at the doses of 250 and 500 mg/kg per day
divided into three administrations for three consecutive days (at least
n = 5 mice per group). After 3 days of treatment, the animals were sac-
rificed and various organs (brain, liver, and muscle) were collected after
cardiac perfusion with phosphate-buffered saline (PBS). For crude
mitochondria purification, fresh tissue was placed in cold 20 mM
Hepes, 5 mM EDTA Na2, 0.25 M sucrose, 1 mM phenylmethylsulfonyl
fluoride, and 1 mM phenanthroline (pH 7.4). Tissues were minced and
washed in buffer, and the homogenate was centrifuged for 15 min at
1000g at 4°C to remove unbroken cells and nuclei. Supernatants were cen-
trifuged at 10,000g at 4°C for 15 min. For purification of crude mitochon-
dria from muscles, fresh tissues were harvested and placed in 20 mM
Hepes, 1mMEDTANa2, 100mMKCl, 0.3% bovine serum albumin (BSA),
and 2 mM 2-mercaptoethanol (pH 7.4). Tissues were minced and washed
in buffer, and the homogenate was centrifuged at 800g for 10 min at 4°C to
remove unbroken cells and nuclei. Supernatants were combined and cen-
trifuged at 10,000g for 10 min at 4°C. The pellets were resuspended in
MSEM buffer [220 mM mannitol, 70 mM sucrose, 1 mM EDTA Na2,
5 mMMops (pH 7.4)] and centrifuged at 20,000g for 10 min at 4°C. Mito-
chondrial extracts from brains, muscles, and livers were stored at −80°C.
Serum phenylbutyrate and phenylacetate concentrations were de-
termined by tandem mass spectrometry according to a previously re-
ported method (25).
Partial hepatectomy in 12-week-old C57BL/6 male mice was per-
formed according to standard procedure (59). The animals were ran-
domly separated into partial hepatectomy group with saline and partial
hepatectomy group with phenylbutyrate (500 mg/kg per day, divided
into three daily administrations). Saline or phenylbutyrate was admin-
istered by gavage from the day before the partial hepatectomy and
continued up to 72 hours after the intervention (n = 5 per group). Blood
samples were collected at baseline and 24, 48, 72, and 96 hours after
hepatectomy. Blood samples were collected from a small incision with
a scalpel blade on the lateral tail vein in mice anesthetized with isoflurane;
10 ml of whole blood was immediately placed in 100 ml of ice-cold 1.2 M
HClO4 and centrifuged at 1500g for 10 min. Supernatants were collected
and stored at −80°C until analysis. Lactate determinations were performed
by lactate dehydrogenase assay (Sigma) adding lactate dehydrogenase
and NAD+ (nicotinamide adenine dinucleotide) to the supernatants.
After 15 min of incubation at 37°C, absorbance at 340 nm was mea-
sured to determine lactate concentrations. Each lactate measurement
was performed in duplicate.
Enzyme assays
For PDH enzyme assays, cells were harvested with trypsin solution
and centrifuged. After centrifugation, the pellets were washed twice
with PBS. The cell pellet was resuspended in 2 ml of buffer A [Mops,
20 mM KOH (pH 7.4), 250 mM sucrose] and 0.2 mg of digitonin for
every milliliter of buffer A. The solution was mixed and kept on ice for
5 min and centrifuged at 5000g for 3 min. The supernatant was mixed
with 3 ml of buffer B [Mops, 20 mM KOH (pH 7.4), 250 mM sucrose,
1 mM EDTANa4], kept on ice for 5 min, and then centrifuged at 10,000g
for 3 min. The supernatant was discarded, and pellets were resuspended
in 0.5 ml of 20 mM K-phosphate buffer (pH 7.4), then frozen in liquid
nitrogen, and thawed at 37°C three times. Pellets were stored at −80°C
and used for enzyme assays. PDHC enzyme activity was measured in
mitochondrial extracts as described previously (60). Briefly, the assay
mixture contained 30 mM Hepes-KOH, 10 mM b-mercaptoethanol,
1 mM CoASH, 0.1 mM NAD [nicotinamide adenine dinucleotide (oxi-www.Sciedized form)], 0.3 mM thiamine pyrophosphate, 0.02% Triton, 10 mM
MgCl2, and 1 mMCaCl2. The enzyme reaction was initiated with 20 mM
of [14C]Na-pyruvate (PerkinElmer) and incubated for 10 min at 37°C.
Reaction was terminated with 250 ml of 1 N HCl on ice and left at 37°C
for 60 min. The 14CO2 released from the reaction was captured onto filter
paper and transferred in scintillation liquid overnight; the amount of 14C
was counted by a b counter (Packard Tri-Carb 2100 TR). PDHC enzyme
activity was expressed as nanomoles per minute per milligram of protein.
Western blots
Pellets of crude mitochondria were rehomogenized in cold lysis buffer
[50 mM tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, and 0.1% SDS] in the presence of protease inhibitors (Sigma).
Total proteins quantified by the Bradford method were resolved by
SDS-PAGE and transferred onto a PVDF membrane.
Western blot analyses with 10 mg of mitochondria were per-
formed with PhosphoDetect anti–PDH-E1a (p-Ser264-a; Calbiochem
AP1062), PhosphoDetect anti–PDH-E1a (p-Ser203-a; Calbiochem AP1063),
PhosphoDetect anti–PDH-E1a (p-Ser271-a; Calbiochem AP1064), anti–
cytochrome c oxidase IV (COXIV; Cell Signaling Technology Inc.), anti–
PDH-E1a (Abcam ab110416), and HRP-conjugated secondary antibodies
(GE Healthcare) diluted in 5% milk in TBST and in 1% BSA in TBST.
Bands were visualized with a chemiluminescence detection system (Pierce).
Real-time polymerase chain reaction
Fibroblasts and mouse tissues were homogenized with 1 ml of TRIzol
(Qiagen Inc.) with TissueLyser (Qiagen Inc.) for 2 min at 20 Hz, and
total RNA from brains was extracted with RNeasy Lipid Tissue Mini
Kit (Qiagen Inc.). The concentration and purity of total RNA were as-
sessed spectrophotometrically at 260 and 280 nm. Agarose gel electro-
phoresis was performed to confirm the presence of 18S ribosomal RNA
(rRNA) and 28S rRNA. First-strand complementary DNA (cDNA) was
synthesized from total RNA with a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Sequences of primers for hu-
man genes PDHA1, PDHA2, PDHB, DLAT, DDLD, PDP1, PDP2,
PDHX, PDK1, PDK2, PDK3, PDK4, and b-actin are shown in table S2.
Sequences of primers for mouse genes Pdha1, Pdha2, Pdhb, Pdhx, Pdk1,
Pdk2, Pdk3, Pdk4, Pdp1, Pdp2, Dlat, Dld, CoxIV, and b2-microglobulin
are shown in table S3. Quantitative real-time polymerase chain reaction
(PCR) was performed with SYBR Green in LightCycler 480 multiwell
plates (Roche).
The real-time reaction mixture contained 2 ml of a 1:20 dilution of
cDNA, 12.5 ml of LightCycler 480 SYBR Green I Master Mix (Roche),
and 10.5 ml of gene-specific primers in a final reaction volume of 25 ml.
The cycling conditions were as follows: preincubation at 95°C for 5 min;
45 cycles of amplification and quantification at 95°C for 10 s, 60°C for
10 s, and 72°C for 15 s; melting curve program at 95°C for 5 s, 65°C for
1 min, and 97°C for continuous fluorescence measurement; and finally
a cooling step at 40°C for 20 min. Calculations were made by the 2−DDCT
method, where CT is defined as the threshold cycle for target amplifica-
tion. The data are presented as fold changes in target gene expression in
cells or tissues normalized to the internal control gene (b-actin or b2-
microglobulin) and relative to the untreated tissue or cells. For the un-
treated or saline-treated control samples, DDCT equals zero, and because
20 equals one, the fold change in gene expression relative to the un-
treated control equals one, by definition. For treated samples, evaluation
of 2−DDCT indicates the fold change in gene expression relative to the
untreated or saline-treated control.nceTranslationalMedicine.org 6 March 2013 Vol 5 Issue 175 175ra31 8
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 PDK activity assay
Recombinant human PDK2 (SRP5248, Sigma-Aldrich), PDHA1 (30
to 390) (SRP5238, Sigma-Aldrich), and pyruvate dehydrogenase E2
peptide (ab73826, Abcam) were used for these studies.
PDK activity was measured in duplicate as the initial rate of incor-
poration of [32P]phosphate into E1 with 0.2 mM [g-32P]ATP (150 to
500 cpm/pmol) at 30°C (61–63). The assay used 0.02 mg of PDK2, and
incorporation was measured after 45 s of reaction time. The assay was
conducted with buffer A, which had a final pH of 7.4 and the following
composition: 113 mMHepes-tris (pH 7.4), 60 mMKCl, 30 mMK-Hepes,
2 mMMgCl2, and 0.2 mM EDTA. The assay mixture in these studies also
contained 2 mM dithiothreitol. Concentrated protein components (8, 4, 3,
2, 1, and 0.5 g of E1 and 7.6, 3.8, 2.8, 1.9, 0.95, and 0.48 g of E2) were
preincubated together for 60 min at 4°C in the buffer in which they were
prepared and then were added to reaction mixtures for 2 min at 30°C
before initiation of PDK2 activity. Phenylbutyrate was added at concen-
trations of 0.25, 0.5, or 1 mM and then the proteins were incubated in
buffer A at 22°C for 60 s, and 0.2 mM [g-32P]ATP was added to a final
volume of 50 ml. The reaction was terminated by adding 2 mM ATP,
and labeled E1 was separated from unbound ATP by loading 35 ml of the
mixture onto G-25 Sephadex gel filtration columns (10 × 0.45 mm). The
reaction mixtures eluted at the void volume (about 200 ml) were applied
to a dry paper (Whatman 3MM, 22 mm) previously soaked in 10% (w/v)
trichloroacetic acid. The assay was completed by reading incorporated
counts per minute in vials containing liquid scintillation cocktail in a
Beckman LS6500 multipurpose scintillation counter. The data were
analyzed with GraFit Data Analysis Software version 5.0.
Docking of phenylbutyrate on PDK
Docking of phenylbutyrate was performed with the Autodock 4.2
force field and the Lamarckian Genetic algorithm in the Autodock
molecular modeling package (R. Abagyan, A. Orry, E. Raush, and
M. Totrov, ICM Manual v.3.0, Molsoft LLC, 2011). The initial PDK
model was generated in Autodock by building hydrogen atoms for the
crystal structure of human PDK2 (PDB chain ID 2BU7) and adding
Gasteiger charges. An initial conformation of the ligand phenylbuty-
rate was generated by Cartesian optimization of the ligand model in
GROMOS87 force field (PRODRG at http://davapc1.bioch.dundee.ac.
uk/prodrg/submit2.html). All side chains and the backbone of the protein
were kept rigid as in the crystal structure. Docking was performed first by
placing the ligand in a random position by centering the grid on the mac-
romolecule and setting the grid with a 1-Å spacing on the entire protein;
after the identification of the best binding sites, a further analysis was
performed by starting with the ligand in the binding pockets and setting
the grid with a 0.375-Å spacing. The global energy of the complex was
calculated as a sum of van der Waals, electrostatic, hydrogen bonding,
and torsion stress terms. In repeated runs, conformation clustering of
10 dockings within a root mean square deviation of 0.5 Å to the over-
all best energy pose of the ligand allowed to identify at least five confor-
mations with distinct binding energy above −5 kcal/mol. Control of
docking procedure was obtained by docking the compound DCA on
the kinase structure (PDB chain ID 2Q8H) after ligand and potassium
ion removal. Pictures were drawn with the tools available under the Auto-
dock 4.2 suite.
Structural analysis of mutations
Structural analysis of PDHA mutations was performed with the 3D
structure of PDHC component (E1) of human PDHC available atwww.Sciethe RCBS PDB (chain ID 3EXE). Coordinates were loaded in the
Swiss PDB Viewer software (Swiss Institute of Bioinformatics), and
analyses of both localization and mutation of these residues were
performed in their structural context with the tools available under
the Swiss PDB Viewer software. 3D structures of the proteins were
drawn with PyMol software (DeLano Scientific LLC).
Zebrafish studies
The noa strain carrying the m631 allele was obtained from the
Zebrafish International Resource Center (ZIRC), University of
Oregon, and maintained as described (64). The noam631 mutants were
treated from 5 to 8 days after fertilization with 0.25 mM phenylbutyr-
ate. For genotyping, DNA was extracted from whole or partial larvae
with 40 ml of extraction buffer [10 mM tris-HCl (pH 8.2), 10 mM
EDTA, 200 mM NaCl, 0.5% SDS, proteinase K (200 mg/ml)] and in-
cubated at 50°C overnight. One hundred microliters of 95% ethanol
was added to the mix, after which it was placed on ice for 20 to 30 min
and centrifuged for 10 min. The supernatant was removed, 200 ml of
70% ethanol was added, and samples were centrifuged for 2 min.
DNA was resuspended in 20 ml of TE and used for genotyping with
PCR conditions available at ZIRC (http://zebrafish.org/zirc/fish/pdf/
pcr/m631.pdf ).
To compare the size of melanophores between wild-type, noam631
phenylbutyrate–treated, and noam631 untreated zebrafish, we analyzed
the mean gray value of larvae in the region of the otic vesicle on pho-
tographs taken at 8 days after fertilization. Images were converted to
8-bit grayscale and then processed with the auto-threshold function in
ImageJ software [version 1.46, National Institutes of Health (NIH)]
according to a previously published method (65). After application of
the auto-threshold function, a selection was created by highlighting pixels,
and the mean gray value for the selected area was reported. The images
were taken with a Leica IC80 HD camera. Group averages were cal-
culated for all areas where melanophores were measured, and SDs were
calculated.
Locomotion behavior was videotaped and digitized, and the posi-
tion of each larva in the 48-well plate was determined frame by frame
with NIH image and the “MTrack2” plug-in that tracks particles and
reports their coordinates at each time point after the adjustment of the
threshold. The distance traveled by the larvae in each of 300 frames
and the time (10 s) were plotted on a graph after the conversion of
pixels to micrometers in “R software,” an integrated suite of software
facilities for data manipulation, calculation, and graphical display. The
genotype of each fish was confirmed by PCR after melanophore and
behavioral assays.
Quantification of lactate and pyruvate in zebrafish
Lactate and pyruvate levels were quantified by standard spectro-
photometric analysis (Sigma). The heads of three noam631 mutants
and three wild-type larvae at 8 days after fertilization were cut into
two pieces for DNA extraction and lactate/pyruvate determination, re-
spectively. One piece of each larva was tested for genotype and the
other halves were pooled and homogenized in ice-cold 1.2 M HClO4.
Proteins and insoluble materials were pelleted, exogenous lactate de-
hydrogenase (Sigma) and 5 mM NAD+ (for lactate measurements) or
83 mMNADH (reduced form of NAD+) (for pyruvate measurements)
were added, and the change in absorbance at 340 nm was measured
after 1 hour of incubation at 24°C. Each measurement was performed
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Data are expressed as means ± SD in the bar and line plots. Statistical
significance was computed with the Student’s two-tailed test. A P val-
ue of <0.05 was considered statistically significant.4SUPPLEMENTARY MATERIALS
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Fig. S1. PDHC phosphorylation after phenylbutyrate incubation for 2 and 6 hours in human
wild-type fibroblasts.
Fig. S2. PDHC phosphorylation after drug treatment of human wild-type fibroblasts.
Fig. S3. Expression of PDHC subunits and regulatory enzymes in fibroblasts.
Fig. S4. PDHC phosphorylation status in mouse tissues.
Fig. S5. Expression of PDHC subunits and regulatory enzymes in brain.
Fig. S6. Expression of PDHC subunits and regulatory enzymes in muscle.
Fig. S7. Western blot for PDHC subunits in PDHC-deficient cells.
Table S1. Serum concentrations of phenylbutyrate and phenylacetate in mice.
Table S2. Primers for real-time PCR in human fibroblast RNA.
Table S3. Primers for real-time PCR in RNA from mouse tissues. 
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